Current Report Filing (8-k)
May 09 2019 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 9, 2019
Achillion Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-33095
|
|
52-2113479
|
(State or other jurisdiction of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
1777 Sentry Parkway West,
Building 14, Suite 200,
Blue Bell, PA
|
|
19422
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(215) 709-3040
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
☐
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, Par Value $0.001 per share
|
|
ACHN
|
|
Nasdaq Global Select Market
|
Item 2.02. Results of Operations and Financial Condition
On May 9, 2019, Achillion Pharmaceuticals, Inc. (the Company) announced its financial results for the fiscal quarter ended March 31,
2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form
8-K.
The information in this Form
8-K
(including Exhibit 99.1) shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
Date: May 9, 2019
|
|
ACHILLION PHARMACEUTICALS, INC.
|
|
|
|
|
By: /s/ Brian Di Donato
|
|
|
|
|
Brian Di Donato
|
|
|
|
|
Chief Financial Officer
|
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Sep 2023 to Sep 2024